English  |  正體中文  |  简体中文  |  Total items :2833980  
Visitors :  36129851    Online Users :  618
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 		 
Scope Adv. Search
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR
About TAIR

Browse By
Institution
Author
Title
Date
Statistics Chart
Institution Facts
Trend

News
2019臺灣學術機構典藏
研討會
機構典藏系統RC7版本已
發佈

Copyright
Publisher & Journal Policy
TAIR Copyright Conference Minutes

Related Links
機構典藏計畫網站
ROAR
OpenDOAR
SHERPA
OAIster
JAIRO
Ira
DSPACE
RWWR
臺大學術典藏NTU Scholars
Taiwan Academic Institutional Repository >  Browse by Author

"ou d l"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-50 of 103  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-08-19T00:21:05Z Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma Cheng A.-L.; CHIUN HSU; Wang D.-S.; Lu Y.-S.; Fan H.-H.; Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.
臺大學術典藏 2022-08-19T00:20:55Z Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence Yang T.-H.; Ou D.-L.; CHIUN HSU; Huang S.-H.; Chang P.-L.
臺大學術典藏 2022-08-19T00:20:53Z Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Liu S.-H.; Cheng A.-L.; Lin C.-Y.; Chang C.-Y.; Lin K.-L.; CHIUN HSU; Ou D.-L.; Shen Y.-C.
臺大學術典藏 2022-08-19T00:20:53Z Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway Liou J.-Y.; CHIUN HSU; Cheng A.-L.; Lin L.-I.; Lee B.-S.; Chang Y.-C.; Ou D.-L.
臺大學術典藏 2022-08-19T00:20:46Z H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; Ou D.-L.; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; CHIUN HSU; Lin L.-I.; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y.
臺大學術典藏 2022-08-19T00:20:43Z Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression Ou D.-L.; Cheng A.-L.; Shao Y.-Y.; Feng Z.-R.; Lin L.-I.; Cheng Y.-C.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:40Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy CHIUN HSU; Ou D.-L.; Cheng A.-L.; Chen C.-W.; Tan C.-T.; Lin Y.-Y.
臺大學術典藏 2022-08-19T00:20:40Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.
臺大學術典藏 2022-08-19T00:20:38Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Hsu P.-N.; Cheng A.-L.; CHIUN HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu C.-L.; Lin Y.-Y.; Ou D.-L.
臺大學術典藏 2022-08-19T00:20:30Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:25Z Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Jian C.-Z.; Ou P.-Y.; Ou D.-L.; Hsieh C.-H.; Lin L.-I.; Low G.-S.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:23Z Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma Shao Y.-Y.; Lin L.-I.; Ling A.; CHIUN HSU; Chen P.-S.; Lee B.-S.; Cheng A.-L.; Ou D.-L.
臺大學術典藏 2022-06-10T06:11:04Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:59Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-03-29T07:00:05Z Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; CHING-YU LIN; Liu S.-H.; Cheng A.-L.
臺大學術典藏 2022-03-10T07:58:45Z KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; LI-HUI TSENG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏 2022-03-04T06:53:38Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy Lin Y.-Y.; CHING-TING TAN; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-02-21T02:04:36Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C.
臺大學術典藏 2022-02-21T02:04:35Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C.
臺大學術典藏 2022-02-14T07:10:49Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; YUNG-MING JENG; Hsu C.
臺大學術典藏 2022-02-08T07:49:40Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; SJ TSENG; Kempson I.M.; Hsu C.-L.; Yang P.-C.; Liao Z.-X.
臺大學術典藏 2022-01-24T06:05:32Z Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Hsieh C.-H.; Jian C.-Z.; Lin L.-I.; Low G.-S.; Ou P.-Y.; CHIUN HSU; Ou D.-L.
臺大學術典藏 2022-01-12T07:07:41Z CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia Lin T.-C.; HSIN-AN HOU; Chou W.-C.; Ou D.-L.; Yu S.-L.; Tien H.-F.; Lin L.-I.
臺大學術典藏 2022-01-12T07:07:25Z Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD) Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; HSIN-AN HOU; Hu C.-Y.; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2022-01-12T07:07:10Z Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias Su K.-W.; Ou D.-L.; Fu Y.-H.; Tien H.-F.; HSIN-AN HOU; Lin L.-I.
國立成功大學 2022 Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma Shao, Y.-Y.;Chen, P.-S.;Lin, Lin L.-I.;Lee, B.-S.;Ling, A.;Cheng, A.-L.;Hsu, C.;Ou, D.-L.
臺大學術典藏 2021-09-15T01:20:53Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Ou D.-L.; Lin Y.-Y.; CHIA-LANG HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Hsu C.
臺大學術典藏 2021-09-15T01:20:46Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; CHIA-LANG HSU; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; Hsu C.
臺大學術典藏 2021-09-15T01:20:45Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma CHIA-LANG HSU; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C.
臺大學術典藏 2021-09-15T01:20:45Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; Tseng S.-J.; Kempson I.M.; CHIA-LANG HSU; Yang P.-C.; Liao Z.-X.
臺大學術典藏 2021-09-01T01:54:19Z Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:54:12Z Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells Ou D.-L.; Shen Y.-C.; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:54:08Z IκB kinases increase Myc protein stability and enhance progression of breast cancer cells Yeh P.-Y.; Lu Y.-S.; Ou D.-L.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:53:55Z KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:53:51Z Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:53:48Z Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:25Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:24Z Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:18Z Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:43Z Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L.
臺大學術典藏 2021-08-31T06:29:34Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:32Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:25Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-11T03:46:42Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-08-11T03:46:38Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2021-05-02T03:56:41Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; Tseng S.-J.; Kempson I.M.; Hsu C.-L.; PAN-CHYR YANG; Liao Z.-X.
臺大學術典藏 2021-03-15T07:59:42Z MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine Lu J.-W.;Lin Y.-M.;Lai Y.-L.;Chen C.-Y.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Lin Y.-M.; Lai Y.-L.; Chen C.-Y.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2021-03-15T07:59:41Z Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib Ko Y.-C.;Chung-Yi Hu;Liu Z.-H.;Tien H.-F.;Ou D.-L.;Chien H.-F.;Lin L.-I.; Ko Y.-C.; CHUNG-YI HU; Liu Z.-H.; Tien H.-F.; Ou D.-L.; Chien H.-F.; Lin L.-I.
臺大學術典藏 2021-03-15T07:59:41Z Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD) Lu J.-W.;Wang A.-N.;Liao H.-A.;Chen C.-Y.;Hou H.-A.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; Hou H.-A.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2021-03-09T05:18:38Z Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L.

Showing items 1-50 of 103  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

DSpace Software Copyright © 2002-2004  MIT   &  Hewlett-Packard   /   Enhanced by   NTU Library IR team